At the 61st ASH Annual Meeting & Exposition, Corey Cutler, Dana Farber Cancer Institute, discusses his presentation: The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!
1. What are the major challenges in the treatment of patients with graft-versus-host disease (GvHD)? (0:05)
2. How have recent advances in understanding of the biology of GvHD impacted on patient management? (0:45)
3. What do you consider the most important emerging therapies for GvHD? (1:22)
4. What do healthcare professionals need to know in terms of monitoring and appropriate management of treatment-related adverse events? (1:54)
5. What other key messages of this symposium would you like to highlight? (2:33)
Corey Cutler has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Haematology
Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Bernd Jilma, ASH 2022: The pathophysiology and unmet treatment needs in cold agglutinin disease
Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in this disease. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study […]
Srdan Verstovsek, ASH 2022: Momelotinib long-term safety in myelofibrosis disease – Analysis of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials
Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials – SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, TX, USA) to discuss the limitations of JAK inhibitor therapy in myelofibrosis, and the integrated analysis of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!